What are the clinical indications for propranolol?

Clinical Indications for Propranolol

Propranolol is FDA-approved for hypertension, angina pectoris, migraine prophylaxis, and hypertrophic subaortic stenosis, with additional guideline-supported uses in infantile hemangiomas and anxiety disorders characterized by somatic symptoms. 1

FDA-Approved Indications

Cardiovascular Conditions

• Hypertension: Propranolol may be used alone or combined with thiazide diuretics, but is not indicated for hypertensive emergencies 1
• Angina pectoris due to coronary atherosclerosis: Indicated to decrease angina frequency and increase exercise tolerance 1
• Hypertrophic subaortic stenosis: Improves NYHA functional class in symptomatic patients 1

Migraine Prevention

• Migraine prophylaxis: The American College of Physicians recognizes propranolol as an FDA-approved option for preventing episodic migraine headache 2
• Propranolol is not effective for treating an acute migraine attack that has already started 1

Guideline-Supported Off-Label Indications

Infantile Hemangiomas

• Proliferating infantile hemangiomas: The British Society for Paediatric Dermatology endorses propranolol as treatment for these vascular tumors 2
• Maintenance dose for uncomplicated patients is 2 mg/kg daily, with starting dose of 1 mg/kg daily 2
• Treatment can typically be stopped at 1 year of age, with most patients not requiring treatment beyond 17 months 2
• Important caveat: Ulcerated infantile hemangiomas beyond the growth phase do not require propranolol treatment 2

Anxiety Disorders

• Performance anxiety and somatic anxiety symptoms: The American College of Cardiology recommends propranolol for adolescents with anxiety manifesting primarily as physical symptoms (tremor, palpitations, tachycardia, sweating) 3
• For situational/performance anxiety: 10-20 mg single dose taken 30-60 minutes before the anxiety-provoking event (maximum 40 mg) 3
• For ongoing anxiety symptoms: Initial dosing of 40 mg twice daily, with typical effective range of 80-160 mg daily 3

Critical Care Sedation Reduction

• Mechanically ventilated critically ill adults: Recent high-quality evidence demonstrates propranolol (20-60 mg every 6 hours) significantly reduces sedative requirements by 54% versus 34% in controls, with more sedation assessments within target range (48% vs 35%) 4
• This indication is particularly relevant during sedative shortages and achieved target sedation without increased adverse events 4

Absolute Contraindications

Propranolol must be avoided in the following conditions:

• Cardiogenic shock 1
• Sinus bradycardia and greater than first-degree heart block 1
• Bronchial asthma 1
• Known hypersensitivity to propranolol 1
• Hypoglycemic episodes (recent or ongoing) 2
• Second and third-degree heart block 2

Critical Pre-Treatment Requirements

For Infantile Hemangiomas

• Cardiovascular and respiratory examination required (auscultation, peripheral pulses, abdominal examination) 2
• Pretreatment ECHO and ECG needed only in selected cases 2
• Routine pretreatment FBC, renal, liver, and thyroid profiles are not required 2
• Special consideration for facial segmental hemangiomas: Brain MRI/MRA should ideally be done before starting full dose due to suspected PHACES syndrome; start at 0.5 mg/kg daily before imaging 2

For Adolescent Anxiety

• Screen for absolute contraindications including heart block, decompensated heart failure, asthma, cardiogenic shock, significant hypotension, and history of hypoglycemic episodes 3
• Baseline evaluation must include heart rate and blood pressure measurement, cardiovascular examination, lung auscultation, and screening for diabetes, bronchospasm history, and medications affecting cardiac conduction 3

Common Pitfalls and Safety Warnings

Hypoglycemia Risk

• Propranolol should always be administered with food to reduce hypoglycemia risk 3
• Hold doses during diminished oral intake or vomiting 3
• Glucose checking only required in patients at risk: preterm, low weight, faltering growth, neonates, or history of hypoglycemia 2
• Critical warning for diabetics: Propranolol masks hypoglycemia symptoms 3

Discontinuation

• Never abruptly discontinue propranolol after chronic use; taper gradually over 1-3 weeks 3
• For infantile hemangiomas, it is safe to stop propranolol abruptly during or at end of therapy 2

Drug Interactions

• Avoid routine combination with non-dihydropyridine calcium channel blockers due to increased risk of bradycardia and heart block 3

Monitoring During Treatment

• Monitor for hypotension, bradycardia, fatigue, dizziness, cold extremities, and worsening of heart failure or bronchospasm 3
• For infantile hemangiomas on stable doses: BP and HR do not need monitoring between appointments if infant is well, with routine follow-up every 2-3 months 2